Belimumab in subacute cutaneous lupus erythematosus

Lupus. 2021 Oct;30(12):2017-2018. doi: 10.1177/09612033211033989. Epub 2021 Jul 20.

Authors

Vicenç Torrente-Segarra¹, Laura Peramiquel², Maria Bonet²

Affiliations

¹ Rheumatology Department, Hospital Consorci Sanitari Alt Penedès Garraf (CSAPG), Vilafranca del Penedès, Spain 2Dermatology Department, Hospital Consorci Sanitari Alt Penedès Garraf (CSAPG), Vilafranca del Penedès, Spain.
² Rheumatology Department, Hospital Consorci Sanitari Alt Penedès Garraf (CSAPG), Vilafranca del Penedès, Spain Dermatology Department, Hospital Consorci Sanitari Alt Penedès Garraf (CSAPG), Vilafranca del Penedès, Spain.

PMID: 34284673
DOI: 10.1177/09612033211033989

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Humans
Immunosuppressive Agents / therapeutic use*
Lupus Erythematosus, Cutaneous / diagnosis
Lupus Erythematosus, Cutaneous / drug therapy*
Male
Middle Aged
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
belimumab